Microinjector market seen reaching $3.49 billion by 2030

The microinjector market is projected to climb from $2.15 billion in 2026 to $3.49 billion by 2030, driven by gene editing, precision medicine research and lab automation. North America leads today, while Asia-Pacific is expected to grow fastest.

Why it matters: - Microinjectors sit at the center of cell biology, assisted reproduction and gene editing workflows. - Faster market growth signals rising demand for precision lab tools in both research and clinical settings. - The market’s expansion could benefit fertility treatment, biotechnology and regenerative medicine applications.

What happened: - The microinjector market is projected to grow at a 12.9% compound annual growth rate through 2030. - The market is expected to rise from $2.15 billion in 2026 to $3.49 billion in 2030. - The market grew from $1.9 billion in 2025 to $2.15 billion in 2026, equal to a 13.3% CAGR in the historical period. - The forecast comes from The Business Research Company. - A sample report is available here. - The full report is available here.

The details: - A microinjector delivers very small, precisely controlled amounts of liquid into cells or microscopic targets. - The instrument is used for micromanipulation and can inject genetic substances or reagents under a microscope. - Growth in the historical period was tied to cell biology studies, IVF use, genetic engineering research, funding for life science laboratories and broader micromanipulation adoption. - Future growth is expected to come from gene editing applications, precision medicine investment, laboratory automation, biotechnology research and regenerative medicine development. - Key trends include high-precision microinjection devices, automated micromanipulation workflows, multifunctional microinjectors, high-throughput injection platforms and better accuracy and reproducibility. - Rising infertility is a major demand driver. - Microinjectors help assisted reproductive technologies such as IVF by enabling injection of a single sperm directly into an egg. - The World Health Organization reported in April 2023 that about 17.5% of adults globally, or roughly one in six people, experience infertility. - North America held the largest share of the market in 2025. - Asia-Pacific is expected to grow the fastest during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market outlook reflects a broader shift toward precise, automated lab tools that can support both research scale and clinical consistency. - Fertility treatment remains a practical commercial anchor for the category, while gene editing and precision medicine point to longer-term research demand. - The regional split suggests mature demand in North America and faster adoption potential in Asia-Pacific.

What’s next: - The Business Research Company says its 2026 reports now include expanded strategic intelligence, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and trend analysis. - The company lists Saumya Sahay as a contact for more information, with phone numbers for the Americas, Asia and Europe, plus the email marketing@tbrc.info. - The company also directs readers to its LinkedIn page at The Business Research Company.